Vaccination follows a schedule recommended by the Centers for Disease Control and Prevention (CDC), the American Academy of Pediatrics, the American Academy of Family Physicians, and the American College of Obstetricians and Gynecologists. See tables Recommended Immunization Schedule for Ages 0–6 Years, Recommended Immunization Schedule for Ages 7–18 Years, and Catch-up Immunization Schedule for Ages 4 Months–18 Years.
Practitioners should also check for the CDC's latest recommendations (also available as a free mobile app), consult the CDC's child–adolescent immunization schedules and catch-up immunization schedule, and consult the relevant Advisory Committee on Immunization Practices (ACIP) statements for detailed recommendations and updates. Vaccination status should be reassessed at every visit.
For adverse effects and details of administration of specific vaccines, see Overview of Immunization.
Recommended Immunization Schedule for Ages 0–6 Years
Vaccine |
Birth |
1 month |
2 months |
4 months |
6 months |
9 months |
12 months |
15 months |
18 months |
19–23 months |
2–3 years |
4–6 years |
||
Hepatitis B (HepB)[a] |
1st dose |
2nd dose |
See footnote * |
3rd dose |
See footnote * |
|||||||||
Rotavirus (RV)[b] |
|
|
1st dose |
2nd dose |
See footnote [b] |
|
|
|
|
|
|
|
|
|
Diphtheria, tetanus, acellular pertussis (DTaP, < 7 years)[c] |
|
|
1st dose |
2nd dose |
3rd dose |
See footnote * |
4th dose |
See footnote * |
5th dose |
|||||
Haemophilus influenzae type b (Hib)[d] |
|
|
1st dose |
2nd dose |
See footnote [d] |
See footnote * |
3rd or 4th dose[d] |
See footnote * |
See footnote † |
|||||
Pneumococcal conjugate vaccine (PCV13)[e] |
|
|
1st dose |
2nd dose |
3rd dose |
See footnote * |
4th dose |
See footnote * |
See footnote † |
|||||
Inactivated polio virus (IPV)[f] |
|
|
1st dose |
2nd dose |
3rd dose |
See footnote * |
4th dose |
|||||||
Influenza (inactivated influenza vaccine [IIV])[g] |
|
|
|
|
Yearly, 1 or 2 doses |
|||||||||
Influenza (live-attenuated influenza vaccine [LAIV])[g] |
|
|
|
|
|
|
|
Yearly, 1 or 2 doses NOTE: LAIV was not recommended for the 2017-2018 flu season; LAIV may be used during the 2019-2020 flu season. |
||||||
Measles, mumps, rubella (MMR)[h] |
|
|
|
|
See footnote [h] |
1st dose |
See footnote * |
2nd dose |
||||||
Varicella (VAR)[i] |
|
|
|
|
|
|
1st dose |
See footnote * |
2nd dose |
|||||
Hepatitis A (HepA)[j] |
|
|
|
|
See footnote † |
2-dose series[j] |
See footnote ‡ |
|||||||
Meningococcal vaccine (MenACWY-D for ages ≥ 9 months; MenACWY-CRM for ages ≥ 2 months)[k] |
|
|
See footnotes † and [k] |
|||||||||||
Pneumococcal polysaccharide vaccine (PPSV23)[e] |
|
|
|
|
|
|
|
|
|
See footnotes † and [e] |
||||
* = Range of recommended ages for catch-up immunization. |
||||||||||||||
† = Range of recommended ages for certain high-risk groups. |
||||||||||||||
‡ = Range of recommended ages for catch-up and for certain high-risk groups. |
||||||||||||||
This schedule includes recommendations from the CDC and the ACIP in effect as of February 5, 2019. Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and feasible. A combination vaccine should be used instead of separate injections when appropriate. Considerations should include provider assessment, patient preference, and the potential for adverse events. Vaccination providers should consult the relevant ACIP statement for detailed recommendations. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS) using this site or by calling 800-822-7967. Suspected cases of vaccine-preventable diseases should be reported to the state or local health department. If children fall behind or start late, a catch-up schedule should be followed (see table Catch-up Immunization Schedule for Ages 4 Months–18 Years). For information about contraindications and precautions, see the ACIP's Vaccine Recommendations and Guidelines: Contraindications and Precautions. For calculating intervals between doses, 4 weeks = 28 days. Intervals of ≥ 4 months are determined by calendar months. Vaccine doses given ≤ 4 days before the minimum age or interval are considered valid. Doses given ≥ 5 days earlier than the minimum interval or minimum age are not considered valid and should be repeated as age-appropriate. The repeated dose is given after the invalid dose separated by the recommended minimum interval. For further guidance, see Table 3-1: Recommended and minimum ages and intervals between vaccine doses. Within a number range (eg, 12–18 months), the dash means "through." For information about people with immunocompromising conditions, see the ACIP's Vaccine Recommendations and Guidelines: Altered Immunocompetence. For information about travel vaccine requirements, see the CDC's web site Travelers' Health. For information about vaccinating during an outbreak of a vaccine-preventable disease, contact the state or local health department. |
||||||||||||||
[a] Hepatitis B (HepB) vaccine. Minimum age is at birth. |
|
|||||||||||||
At birth:
|
||||||||||||||
After the birth dose:
|
||||||||||||||
[b] Rotavirus (RV) vaccines. Minimum age is 6 weeks for RV-1 (Rotarix®) and RV-5 (RotaTeq®).
|
||||||||||||||
[c] Diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine. Minimum age is 6 weeks, except for DTaP-IPV vaccines (Kinrix® and Quadracel®), which have a minimum age of 4 years.
|
||||||||||||||
[d] Haemophilus influenzae type b (Hib) vaccine. Minimum age is 6 weeks. Catch-up vaccination:
Conditions that increase risk of Hib infection: The following are recommendations for children at increased risk of Hib infection. (Unimmunized means that the complete routine series was not given if children are aged < 14 months or that no doses were given if children are aged ≥ 14 months.)
|
||||||||||||||
[e] Pneumococcal vaccines. Minimum age is 6 weeks for 13-valent pneumococcal conjugate vaccine (PCV13) and 2 years for 23-valent pneumococcal polysaccharide vaccine (PPSV23). Catch-up vaccination:
Conditions that increase risk of pneumococcal infection: The following are recommendations for children who are aged 2–5 years and who have conditions that put them at risk. These conditions include chronic heart and lung disorders, diabetes mellitus, a cerebrospinal leak, a cochlear implant, and certain immunocompromising conditions (eg, sickle cell disease, asplenia, HIV infection, chronic kidney failure, nephrotic syndrome, certain cancers, treatment with immunosuppressants, solid organ transplantation, multiple myeloma). For further guidance, see the ACIP's recommendations for use of the pneumococcal vaccine in children. For recommendations for children aged 7–18 years, see table Recommended Immunization Schedule for Children and Adolescents Ages 7–18 Years).
|
||||||||||||||
[f] Inactivated poliovirus vaccine (IPV). Minimum age is 6 weeks.
Catch-up vaccination:
For series that contain oral polio vaccine (OPV), either only OPV or mixed OPV-IPV:
|
||||||||||||||
[g] Influenza vaccine (seasonal). Minimum age is 6 months for inactivated influenza vaccine (IIV) and 2 years for live-attenuated influenza vaccine (LAIV). NOTE: Live-attenuated influenza vaccine (LAIV) was not recommended for the 2017–2018 flu season; LAIV may be used during the 2019–2020 flu season.
|
||||||||||||||
[h] Measles, mumps, and rubella (MMR) vaccine. Minimum age is 12 months for routine vaccination.
|
||||||||||||||
[i] Varicella (VAR) vaccine. Minimum age is 12 months. |
||||||||||||||
[j] Hepatitis A (HepA) vaccine. Minimum age is 12 months. Catch-up vaccination: International travel: Increased risk of hepatitis A: Unvaccinated children are vaccinated if they are at increased risk of hepatitis A. Risk factors include
For further guidance, see the CDC's Hepatitis A Vaccination: Information for Health Care Providers. |
||||||||||||||
[k] Serogroup A, C, W, Y meningococcal vaccines. Minimum age is 2 months for MenACWY-CRM (Menveo®) and 9 months for MenACWY-D (Menactra®). Routine vaccination is a 2-dose series, given at ages 11–12 years and 16 years, but the vaccine is given to younger children who are at increased risk. For children who have persistent complement component deficiency (including those taking eculizumab) or anatomic or functional asplenia, sickle cell disease, or HIV infection: One of the following can be used:
For children who live in or are traveling to countries where meningococcal disease is hyperendemic or epidemic:
The CDC also recommends vaccinating people identified as being at increased risk during a meningococcal disease outbreak. For further guidance, see the ACIP's meningococcal vaccine recommendations, particularly the ACIP's recommendations for the use of MenACWY-CRM in children. |
||||||||||||||
ACIP = Advisory Committee on Immunization Practices; CDC = Centers for Disease Control and Prevention; PRP-OMP = Neisseria meningitidis polyribosyl ribitol phosphate/outer membrane protein. |
||||||||||||||
Adapted from the CDC: Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2019. Available here. |
Recommended Immunization Schedule for Ages 7–18 Years
Vaccine |
7–10 years |
11–12 years |
13–15 years |
16 years |
17–18 years |
||
Hepatitis B (HepB)[a] |
See footnote * |
||||||
Haemophilus influenzae type b (Hib)[b] |
See footnotes † and [b] |
||||||
See footnotes † and [c] |
|||||||
Inactivated poliovirus (IPV)[d] |
See footnotes * and [d] |
||||||
Influenza inactivated influenza vaccine [IIV][e] |
Yearly, 1 or 2 doses (age 6 months–8 years) |
Yearly, 1 dose |
|||||
Live-attenuated influenza vaccine [LAIV][e] |
Yearly, 1 or 2 doses (age 2–8 years) |
Yearly, 1 dose NOTE: LAIV was not recommended for the 2017–2018 flu season; LAIV may be used during the 2019–2020 flu season. |
|||||
Measles, mumps, rubella (MMR)[f] |
See footnotes * and [f] |
||||||
Varicella (VAR)[g] |
See footnote * |
||||||
Hepatitis A (HepA)[h] |
See footnote ‡ |
||||||
Meningococcal vaccines, quadrivalent (MenACWY-D and MenACWY-CRM)[i] |
See footnote † |
First dose |
See footnote †
|
2nd dose |
See footnote † |
||
Tetanus, diphtheria, acellular pertussis (Tdap)[j] |
See footnote * |
Tdap |
See footnote ‡ |
||||
Human papillomavirus (HPV)[k] |
|
See footnotes † and § |
See footnote [k] |
See footnote * |
|||
|
See footnotes † and [l] |
||||||
|
See footnote § |
||||||
* = Range of recommended ages for catch-up immunization. |
|||||||
† = Range of recommended ages for certain high-risk groups. |
|||||||
‡ = Range of recommended ages for catch-up and for certain high-risk groups. |
|||||||
§ = Range of recommended ages for groups that are not high-risk but may be given the vaccine based on clinical judgment. |
|||||||
This schedule includes recommendations from the CDC and the ACIP in effect as of February 5, 2019. Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and feasible. A combination vaccine should be used instead of separate injections when appropriate. Vaccination providers should consult the relevant ACIP statement for detailed recommendations. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS) using this site or by calling 800-822-7967. Suspected cases of vaccine-preventable diseases should be reported to the state or local health department. If children fall behind or start late, a catch-up schedule should be followed (see table Catch-up Immunization Schedule for Ages 4 Months–18 Years). For information about contraindications and precautions, see the ACIP's Vaccine Recommendations and Guidelines: Contraindications and Precautions. For calculating intervals between doses, 4 weeks = 28 days. Intervals of ≥ 4 months are determined by calendar months. Vaccine doses administered ≤ 4 days before the minimum age or interval are considered valid. Doses administered ≥ 5 days earlier than the minimum interval or minimum age are not considered valid and should be repeated as age-appropriate. The repeated dose is given after the invalid dose separated by the recommended minimum interval. For further guidance, see Table 3-1: Recommended and minimum ages and intervals between vaccine doses. For information about people with immunocompromising conditions, see the ACIP's Vaccine Recommendations and Guidelines: Altered Immunocompetence. For information about travel vaccine requirements, see the CDC's web site Travelers' Health. For information about vaccinating during an outbreak of a vaccine-preventable disease, contact the state or local health department. |
|||||||
[a] Hepatitis B (HepB) vaccine.
|
|||||||
[b] Haemophilus influenzae type b (Hib) conjugate vaccine.
|
|||||||
[c] Pneumococcal vaccines (13-valent pneumococcal conjugate vaccine [PCV13] and 23-valent pneumococcal polysaccharide vaccine [PPSV23]). Conditions that increase risk of pneumococcal infection: The following are recommendations for children who are aged 6–18 years and who have conditions that increase the risk of pneumococcal disease. Chronic heart or lung disorders or diabetes mellitus: Cerebrospinal leak or a cochlear implant:
Certain immunocompromising conditions (eg, sickle cell disease, other hemoglobinopathies, immunodeficiency, asplenia, HIV infection, chronic kidney failure, nephrotic syndrome, certain cancers, treatment with immunosuppressants, solid organ transplantation, multiple myeloma):
Chronic liver disease or alcoholism: If the PCV13 series is incomplete, the number and timing of additional PCV13 doses are determined by the age when first dose was given. For further guidance, see the ACIP's recommendations for use of the pneumococcal vaccine in children. |
|||||||
[d] Inactivated poliovirus vaccine (IPV). For series that contain oral polio vaccine (OPV), either only OPV or mixed OPV-IPV:
|
|||||||
[e] Influenza vaccines (inactivated influenza vaccine [IIV] and live-attenuated influenza vaccine [LAIV]).
|
|||||||
[f] Measles, mumps, and rubella (MMR) vaccine. |
|||||||
[g] Varicella (VAR) vaccine.
|
|||||||
[h] Hepatitis A (HepA) vaccine. Catch-up vaccination: Increased risk of hepatitis A: Unvaccinated children are vaccinated if they are at increased risk of hepatitis A. Risk factors include
For further guidance, see the CDC's Hepatitis A Vaccination: Information for Health Care Providers. |
|||||||
[i] Serogroup A, C, W, Y meningococcal vaccines (MenACWY-CRM [Menveo®] and MenACWY-D [Menactra®]):
Catch-up recommendations for children who have persistent complement component deficiency (including those taking eculizumab), anatomic or functional asplenia, sickle cell disease, or HIV infection: One of the following can be used: Catch-up recommendations for children who live in or are traveling to countries where meningococcal disease is hyperendemic or epidemic: The CDC recommends vaccinating people identified as being at increased risk during a meningococcal disease outbreak. Which vaccine they should receive depends on the serogroup causing the outbreak. For further guidance (including use in patients at increased risk), see the ACIP's meningococcal vaccine recommendations and the CDC's The Pink Book: Meningococcal Disease. |
|||||||
[j] Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine. Minimum age is 11 years for routine vaccination and 7 years for catch-up vaccination.
|
|||||||
[k] Human papillomavirus (HPV) vaccine. Minimum age is 9 years. The number of doses (2 or 3 doses) depends on age at the first dose:
Special situations:
|
|||||||
[l] Serogroup B meningococcal vaccines (MenB [Bexsero®, Trumenba®]). Minimum age is 10 years.
Conditions that increase risk of meningococcal B infection: The following are recommendations for children and adolescents who have conditions that put them at risk. These conditions include having anatomic or functional asplenia, sickle cell disease, and persistent complement component deficiency (including use of eculizumab): |
|||||||
ACIP = Advisory Committee on Immunization Practices; CDC = Centers for Disease Control and Prevention. |
|||||||
Adapted from the CDC: Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2019. Available here. |
Catch-up Immunization Schedule for Ages 4 Months–18 Years
Vaccine |
Minimum Age for Dose 1 |
Minimum Interval Between Doses 1 and 2 |
Minimum Interval Between Doses 2 and 3 |
Minimum Interval Between Doses 3 and 4 |
Minimum Interval Between Doses 4 and 5 |
For ages 4 months–6 years |
|||||
Hepatitis B (HepB)[a] |
Birth |
4 weeks |
8 weeks and at least 16 weeks after the first dose Minimum age for the final dose: 24 weeks |
— |
— |
Rotavirus (RV)[b] |
6 weeks Maximum age for the first dose: 14 weeks, 6 days |
4 weeks |
4 weeks[b] |
— |
— |
Diphtheria, tetanus, acellular pertussis (DTaP)[c] |
6 weeks |
4 weeks |
4 weeks |
6 months |
6 months[c] |
Haemophilus influenzae type b (Hib)[d] |
6 weeks |
4 weeks if the first dose was administered at age < 12 months 8 weeks (as the final dose) if the first dose was administered at age 12–14 months No further doses needed if the first dose was administered at age ≥ 15 months |
4 weeks[d] if the current age is < 12 months and the first dose was administered at age < 7 months and ≥ 1 previous dose was PRP-T (ActHib®, Pentacel®, Hiberix®) or unknown 8 weeks and age 12–59 months (as the final dose)[d] if one of the following is present: or or No further doses needed if the previous dose is administered at age ≥ 15 months |
8 weeks (as the final dose) Only necessary for children aged 12–59 months who received 3 dose before age 12 months |
— |
6 weeks |
4 weeks if the first dose was administered at age < 12 months. 8 weeks (as the final dose for healthy children) if the first dose was administered at age 12–14 months No further doses needed for healthy children if the first dose is administered at age ≥ 24 months |
4 weeks if the current age is < 12 months and the previous dose was given at age < 7 months 8 weeks (as the final dose for healthy children) if one of the following is present: or No further doses needed for healthy children if the previous dose is administered at age ≥ 24 months |
8 weeks (as the final dose) Only necessary for children aged 12–59 months who received 3 doses before age 12 months or for high-risk children who received 3 doses at any age |
— |
|
Inactivated polio virus (IPV)[f] |
6 weeks |
4 weeks[f] |
4 weeks[f] if the current age is < 4 years 6 months as the final dose if the current age is ≥ 4 years |
6 months[f] Minimum age: 4 years for the final dose |
— |
Meningococcal ACWY[g] |
6 weeks |
8 weeks[g] |
See footnote [g] |
See footnote [g] |
— |
Measles, mumps, rubella (MMR)[h] |
12 months |
4 weeks |
— |
— |
— |
Varicella (VAR)[i] |
12 months |
3 months |
— |
— |
— |
Hepatitis A (HepA)[j] |
12 months |
6 months |
— |
— |
— |
For ages 7–18 years |
|||||
Tetanus, diphtheria (Td) Tetanus, diphtheria, acellular pertussis (Tdap)[k] |
7 years[k] |
4 weeks |
4 weeks if the first dose of DTaP/DT was administered at age < 12 months 6 months (as the final dose) if the first dose of DTaP/DT or Tdap/Td was administered at age ≥12 months |
6 months if the first dose of DTaP/DT was administered at age < 12 months |
— |
Human papillomavirus (HPV)[l] |
9 years |
Routine dosing intervals recommended[l] |
|||
Hepatitis A (HepA)[j] |
N/A |
6 months |
— |
— |
— |
Hepatitis B (HepB)[a] |
N/A |
4 weeks |
8 weeks and at least 16 weeks after the first dose |
— |
— |
Inactivated polio virus (IPV)[f] |
N/A |
4 weeks |
6 months[f] A 4th dose not necessary if the 3rd dose was administered at age ≥ 4 years and at least 6 months after the previous dose |
A 4th dose of IPV required if all previous doses were administered at age < 4 years or if the 3rd dose was administered < 6 months after the 2nd dose |
— |
Meningococcal ACWY conjugate[g] |
N/A |
8 weeks[g] |
— |
— |
— |
Measles, mumps, rubella (MMR)[h] |
N/A |
4 weeks |
— |
— |
— |
Varicella (VAR)[i] |
N/A |
3 months if age is < 13 years 4 weeks if age is ≥ 13 years |
— |
— |
— |
NOTE: For children whose vaccinations were started late or are > 1 month behind, this table provides catch-up schedules and minimum intervals between doses (see also the CDC's recommended catch-up immunization schedule). A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child’s age. Always use this table in conjunction with the CDC's child and adolescent immunization schedules, including their footnotes (see also table Recommended Immunization Schedule for Ages 0–6 Years and table Recommended Immunization Schedule for Ages 7–18 Years). Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS) using this site or by calling 800-822-7967. Suspected cases of vaccine-preventable diseases should be reported. For information about contraindications and precautions, see the ACIP's Vaccine Recommendations and Guidelines: Contraindications and Precautions. For calculating intervals between doses, 4 weeks = 28 days. Intervals of ≥ 4 months are determined by calendar months. Vaccine doses administered ≤ 4 days before the minimum age or interval are considered valid. Doses administered ≥ 5 days earlier than the minimum interval or minimum age are not considered valid and should be repeated as age-appropriate. The repeated dose is given after the invalid dose separated by the recommended minimum interval. For further guidance, see Table 3-1: Recommended and minimum ages and intervals between vaccine doses. For information about travel vaccine requirements, see the CDC's web site Travelers' Health. For information about vaccinating during an outbreak of a vaccine-preventable disease, contact the state or local health department. |
|||||
[a] Hepatitis B (HepB) vaccine. |
|||||
[b] Rotavirus (RV) vaccines. |
|||||
[c] Diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine. |
|||||
[d] Haemophilus influenzae type b (Hib) conjugate vaccine.
Conditions that increase risk of Hib infection: The following are recommendations for children at increased risk of Hib infection. (Unimmunized means that the complete routine series was not given if children are aged up to 14 months or that no doses were given if children are aged ≥ 14 months.)
|
|||||
[e] Pneumococcal vaccines. Minimum age is 6 weeks for 13-valent pneumococcal conjugate vaccine (PCV13) and 2 years for 23-valent pneumococcal polysaccharide vaccine (PPSV23). For further guidance, see the ACIP's recommendations for use of the pneumococcal vaccine in children. Conditions that increase risk of pneumococcal infection: The following are catch-up recommendations for children have conditions that put them at risk. These conditions include chronic heart and lung disorders, diabetes mellitus, a cerebrospinal leak, a cochlear implant, certain immunocompromising conditions (eg, sickle cell disease, other hemoglobinopathies, asplenia, HIV infection, chronic kidney failure, nephrotic syndrome, certain cancers, treatment with immunosuppressants), solid organ transplantation, multiple myeloma, chronic liver disease, and alcoholism. For children aged 2–5 years with any condition that increases risk:
For children and adolescents aged 6–18 years with chronic heart or lung disorders or diabetes mellitus: For children and adolescents aged 6–18 years with a cerebrospinal leak or a cochlear implant:
For children and adolescents aged 6–18 years with certain immunocompromising conditions (eg, sickle cell disease, other hemoglobinopathies, asplenia, HIV infection, chronic kidney failure, nephrotic syndrome, certain cancers, treatment with immunosuppressants):
For children and adolescents aged 6–18 years with chronic liver disease or alcoholism: If the PCV13 series is incomplete, the number and timing of additional PCV13 doses are determined by the age when first dose was given. For further guidance, see the ACIP's recommendations for use of the pneumococcal vaccine in children. |
|||||
[f] Inactivated poliovirus vaccine (IPV).
For series that contain oral polio vaccine (OPV), either only OPV or mixed OPV-IPV:
|
|||||
[g] Serogroup A, C, W, Y meningococcal vaccines (MenACWY-CRM [Menveo®] and MenACWY-D [Menactra®]).
|
|||||
[h] Measles, mumps, and rubella (MMR) vaccine. |
|||||
[i] Varicella (VAR) vaccine.
|
|||||
[j] Hepatitis A (HepA) vaccine.
Increased risk of hepatitis A: Unvaccinated children are vaccinated if they are at increased risk of hepatitis A. Risk factors include
For further guidance, see the CDC's Hepatitis A Vaccination: Information for Health Care Providers. |
|||||
[k] Tetanus and diphtheria toxoids (Td) and tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccines.
|
|||||
[l] Human papillomavirus (HPV) vaccine. The number of doses (2 or 3 doses) depends on age at the first dose:
|
|||||
ACIP = Advisory Committee on Immunization Practices; CDC = Centers for Disease Control and Prevention; N/A = not applicable; PRP-OMP = Neisseria meningitidis polyribosyl ribitol phosphate/outer membrane protein. Adapted from the CDC: Catch-up immunization schedule for persons aged 4 months–18 years who start late or who are more than 1 month behind, United States, 2019. Available here. |
More Information
Drugs Mentioned In This Article
Drug Name | Select Trade |
---|---|
immune globulin |
Gammagard S/D |
eculizumab |
SOLIRIS |